<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190502</url>
  </required_header>
  <id_info>
    <org_study_id>KD CD IKEM 1</org_study_id>
    <secondary_id>NB/6541-3 IGA MZCR</secondary_id>
    <nct_id>NCT00190502</nct_id>
  </id_info>
  <brief_title>Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes</brief_title>
  <official_title>The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is:&#xD;
&#xD;
        -  To compare the effect of ATG treatment together with intensified insulin therapy (Group&#xD;
           1) on fasting and glucagon-stimulated C-peptide production with that of intensified&#xD;
           insulin therapy only (Group 2) in type 1 diabetes mellitus of recent onset&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To compare the insulin doses between the two groups at 6, 12, 18, and 24 months after&#xD;
           diabetes onset&#xD;
&#xD;
        -  To compare the course of the specific humoral markers of autoimmunity between the groups&#xD;
&#xD;
        -  To evaluate the significance of in vitro testing of specific T-cell activation by an&#xD;
           autoantigen in the long-term follow-up in type 1 diabetes&#xD;
&#xD;
        -  To assess the safety of ATG treatment in type 1 diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, single-blind and parallel group study. After admission to&#xD;
      the hospital, initial physical and laboratory examinations will be performed. Laboratory&#xD;
      tests and medical treatment not related to the experimental protocol (except for&#xD;
      immunosuppressive drugs) will be performed as clinically needed. Patients who fulfill the&#xD;
      inclusion criteria and give their informed consent to participate in the study will be&#xD;
      randomized to be treated either with a course of ATG-Fresenius together with intensified&#xD;
      insulin therapy (Group 1) or with intensified insulin therapy only (Group 2).&#xD;
&#xD;
      For the study purpose, clinical and laboratory status of the patients will be assessed at 14&#xD;
      occasions (screening, visit 1 - visit 14). Thereafter, an extended follow-up study is planned&#xD;
      with evaluations every 6 months.&#xD;
&#xD;
      Patients will be referred to the research institution by cooperating general practitioners&#xD;
      and diabetes specialists, preferably before initiation of insulin therapy. After diabetes&#xD;
      confirmation (according to WHO criteria) and initial clinical and biochemical examinations&#xD;
      (typical for all patients with recent onset diabetes) the purpose, potential risk and&#xD;
      benefits and the design of the study will be explained. Subjects willing to participate in&#xD;
      the study will be asked to give their written informed consent.&#xD;
&#xD;
      All patients will be actively educated in diabetes management and intensified insulin therapy&#xD;
      (3 - 4 daily injections of human insulin, glucose self-monitoring) will be initiated&#xD;
      according to individual needs. In subjects randomized to Group 1, 4 doses of ATG Fresenius&#xD;
      (first dose of 9 mg/kg of body weight, then 3 consecutive doses of 3 mg/kg) will be&#xD;
      administered intravenously over 4 hours. Subjects in Group 2 will be treated with saline&#xD;
      infusion (500 ml) on the same days. 1 hour before the first ATG administration, a cutaneous&#xD;
      tolerance test (0.2 ml of the final solution) will be performed. Approximately 10 days after&#xD;
      admission the patients will be dismissed. Besides scheduled ambulant visits, all subjects&#xD;
      will be followed-up as clinically needed. In Paediatric patients (age 15-18 years),&#xD;
      recommendations of a paediatric endocrinologist concerning diabetes management will be&#xD;
      respected.&#xD;
&#xD;
      After completion of the study each patient's diabetes specialist will be acquainted with the&#xD;
      course of the treatment so far and the patients will be treated according to individual&#xD;
      needs. They will be seen regularly once per year in the Department of Diabetes in IKEM for&#xD;
      the next 3 years.&#xD;
&#xD;
      Discontinuation of the study:&#xD;
&#xD;
      Participation in the study may be at all times stopped according to the patient's will.&#xD;
      Should this require the medical status of the patients, the study may be interrupted based on&#xD;
      the investigator's decision during the period of ATG administration.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Twenty four patients with type 1 diabetes mellitus of recent onset will be followed in the&#xD;
      Institute for Clinical and Experimental Medicine in Prague. Inclusion criteria will be:&#xD;
&#xD;
        -  Type 1 diabetes mellitus of known duration up to 6 weeks&#xD;
&#xD;
        -  Men and women 15 - 35 years old, body mass index up to 32 kg/m2, exclusion of gravidity&#xD;
           in women&#xD;
&#xD;
        -  Insulin dose up to 40 IU per day for no longer than 1 month&#xD;
&#xD;
        -  C-peptide level ≥ 0.3 pmol/ml 4 min. following iv. administration of 1 ml glucagon&#xD;
&#xD;
        -  No previous immunosuppressive therapy, no concurrent severe infection, granulocyte count&#xD;
           ≥ 2 x 10^9/l, platelet count ≥ 120 x 10^9/l&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2000</start_date>
  <completion_date>December 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Educational/Counseling/Training</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide production</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes remission rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
  </secondary_outcome>
  <enrollment>28</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyclonal anti-T-cell antibodies</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Body mass index up to 32 kg/m2&#xD;
&#xD;
          -  Exclusion of gravidity in women&#xD;
&#xD;
          -  Known diagnosis of diabetes of less than 6 weeks&#xD;
&#xD;
          -  Insulin dose of up to 40 IU per day for no longer than 1 month&#xD;
&#xD;
          -  Positive for at least one autoantibody (GAD, IA2, ICA)&#xD;
&#xD;
          -  C-peptide level ≥ 0.3 pmol/ml 4 min. following intravenous (IV) administration of 1 ml&#xD;
             glucagon&#xD;
&#xD;
          -  No concurrent severe infection&#xD;
&#xD;
          -  Granulocyte count ≥ 2 x 10^9/l&#xD;
&#xD;
          -  Platelet count ≥ 120 x 10^9/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other non-diabetes related autoimmune disease&#xD;
&#xD;
          -  Previous immunosuppressive therapy&#xD;
&#xD;
          -  Any clinical impairment precluding immunosuppressive therapy&#xD;
&#xD;
          -  Leucopenia or thrombocytopenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frantisek Saudek, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Clinical and Experimental Medicine, Prague</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frantisek Saudek, MD.</last_name>
    <email>frsa@medicon.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine, Department of Diabetes</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frantisek Saudek, MD.</last_name>
      <email>frsa@medicon.cz</email>
    </contact>
    <investigator>
      <last_name>Frantisek Saudek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petr Boucek, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tereza Havrdova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <results_reference>
    <citation>Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud. 2004 Summer;1(2):80-8. Epub 2004 Aug 10.</citation>
    <PMID>17491669</PMID>
  </results_reference>
  <verification_date>February 2004</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 8, 2007</last_update_submitted>
  <last_update_submitted_qc>January 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2007</last_update_posted>
  <keyword>Type 1 diabetes mellitus</keyword>
  <keyword>Immune intervention</keyword>
  <keyword>Polyclonal antibodies</keyword>
  <keyword>Type 1 diabetes of recent onset</keyword>
  <keyword>C-peptide level 0.3 pmol/l or higher</keyword>
  <keyword>Positivity of at least one marker of autoimmunity (diabetes)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

